ESSA PHARMA INC (EPIX)
CA29668H7085 - Common Stock
Overall EPIX gets a fundamental rating of 3 out of 10. We evaluated EPIX against 561 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for EPIX as it has an excellent financial health rating, but there are worries on the profitability. EPIX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year EPIX has reported negative net income.
In the past year EPIX has reported a negative cash flow from operations.
EPIX had negative earnings in each of the past 5 years.
EPIX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
EPIX has a better Return On Assets (-22.28%) than 74.77% of its industry peers.
With an excellent Return On Equity value of -22.91%, EPIX belongs to the best of the industry, outperforming 83.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.28% | ||
| ROE | -22.91% | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
EPIX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
There is no outstanding debt for EPIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
EPIX has an Altman-Z score of 12.13. This indicates that EPIX is financially healthy and has little risk of bankruptcy at the moment.
EPIX has a better Altman-Z score (12.13) than 87.75% of its industry peers.
EPIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 12.13 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 38.64 indicates that EPIX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 38.64, EPIX belongs to the top of the industry, outperforming 99.10% of the companies in the same industry.
A Quick Ratio of 38.64 indicates that EPIX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 38.64, EPIX belongs to the top of the industry, outperforming 99.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 38.64 | ||
| Quick Ratio | 38.64 |
3. Growth
3.1 Past
The earnings per share for EPIX have decreased by -6.68% in the last year.
EPS 1Y (TTM)-6.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-15.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 71.19% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y25.66%
EPS Next 2Y19.49%
EPS Next 3Y36.9%
EPS Next 5Y71.19%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
EPIX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year EPIX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
EPIX's earnings are expected to grow with 36.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.49%
EPS Next 3Y36.9%
5. Dividend
5.1 Amount
EPIX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ESSA PHARMA INC
NASDAQ:EPIX (1/6/2025, 5:20:01 PM)
After market: 1.92 0 (0%)1.92
+0.06 (+3.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners80.08%
Inst Owner Change0%
Ins Owners2.26%
Ins Owner Change-588.69%
Market Cap85.23M
Analysts48.89
Price Target12.48 (550%)
Short Float %2.19%
Short Ratio0.8
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-35.61%
EPS NQ rev (1m)0%
EPS NQ rev (3m)57.14%
EPS NY rev (1m)0%
EPS NY rev (3m)44.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.68 | ||
| P/tB | 0.68 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.64
EYN/A
EPS(NY)-0.51
Fwd EYN/A
FCF(TTM)-0.51
FCFYN/A
OCF(TTM)-0.51
OCFYN/A
SpS0
BVpS2.81
TBVpS2.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.28% | ||
| ROE | -22.91% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 38.64 | ||
| Quick Ratio | 38.64 | ||
| Altman-Z | 12.13 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-15.22%
EPS Next Y25.66%
EPS Next 2Y19.49%
EPS Next 3Y36.9%
EPS Next 5Y71.19%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-14.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-14.83%
OCF growth 3YN/A
OCF growth 5YN/A